MedCity News
MAY 23, 2023
As pharmaceutical reps are used less and less, the role of the MSL has become more prominent as a conduit between life sciences companies and external stakeholders for drug development.
Clarivate
MARCH 8, 2023
In recent years, there has been an increased focus on real world evidence to advance medical science and improve patient quality of life. Biopharma companies are investing in the use of real world data (RWD) to accelerate innovation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
DECEMBER 23, 2022
With these silos breaking down, biopharmas will have the opportunity to drive a more coordinated approach to HCP engagement using shared data and unified systems, while still maintaining compliance. Given the demand to deliver a steady stream of content to meet HCPs’ needs, pharma marketers must react, create, edit, and adapt quickly.
PM360
NOVEMBER 21, 2022
Combined with the incentives provided by the Orphan Drug Act, a powerful dynamic is at play, ever further pushing the limits of what medical science can achieve. It’s also in these communities where biopharma finds the best opportunities to connect with their stakeholders. Accelerating the Path to Diagnosis and Treatment.
Clarify Health
MAY 19, 2020
There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. sales, medical science liaisons, etc.).
Medgadget
MARCH 22, 2023
Such work requires a lot of data points and they’re working with medical centers, labs, pharma companies, and using public data to continue developing the technology. We hope to see Imagene showing off its technology at Biomed Israel , the leading international Life Science and HealthTech conference in Israel.
Expert insights. Personalized for you.
80 
Let's personalize your content